Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E. Singer, Werner Hacke, Günter Breithardt, Jonathan L. Halperin, Graeme J. Hankey, Jonathan P. Piccini, Richard C. Becker, Christopher C. Nessel, John F. Paolini, Scott D. Berkowitz, Keith A.A. Fox, Robert M. Califf

New England Journal of Medicine, 2011

Clinical Research Institute, Duke Medical Center, Duke University, Johnson & Johnson (United States), Massachusetts General Hospital, Harvard University, Heidelberg University, University Hospital Münster, University of Münster, Mount Sinai Medical Center, Royal Perth Hospital, Bayer (United States), University of Edinburgh, Edinburgh Royal Infirmary

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

9335

Citations

View on Google Scholar

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Abstract

Journal Details

Join JournalsHub

Welcome Back